161 related articles for article (PubMed ID: 31881224)
1. Dihydroartemisinin inhibits endothelial cell tube formation by suppression of the STAT3 signaling pathway.
Gao P; Wang LL; Liu J; Dong F; Song W; Liao L; Wang B; Zhang W; Zhou X; Xie Q; Sun R; Liu J
Life Sci; 2020 Feb; 242():117221. PubMed ID: 31881224
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.
Dong F; Zhou X; Li C; Yan S; Deng X; Cao Z; Li L; Tang B; Allen TD; Liu J
Cancer Biol Ther; 2014; 15(11):1479-88. PubMed ID: 25482945
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin ameliorates retinal vascular dysfunction in diabetes mellitus via the FASN/Kmal-mTOR/SREBP1 feedback loop.
Gu C; She X; Zhou C; Su T; He S; Meng C; Gu Q; Luo D; Zheng Z; Qiu Q
Pharmacol Res; 2021 Dec; 174():105871. PubMed ID: 34619345
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of ERRα inhibits angiogenesis in human umbilical vein endothelial cells through regulating VEGF production and PI3K/Akt/STAT3 signaling pathway.
Zhang LD; Chen L; Zhang M; Qi HJ; Chen L; Chen HF; Zhong MK; Shi XJ; Li QY
Eur J Pharmacol; 2015 Dec; 769():167-76. PubMed ID: 26586335
[TBL] [Abstract][Full Text] [Related]
5. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9.
Rao Q; Yu H; Li R; He B; Wang Y; Guo X; Zhao G; Wu F
Fundam Clin Pharmacol; 2024 Feb; 38(1):113-125. PubMed ID: 37490927
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway.
Dong F; Tian H; Yan S; Li L; Dong X; Wang F; Li J; Li C; Cao Z; Liu X; Liu J
Int J Mol Med; 2015 May; 35(5):1381-7. PubMed ID: 25778668
[TBL] [Abstract][Full Text] [Related]
9. SMND-309 promotes angiogenesis in human umbilical vein endothelial cells through activating erythropoietin receptor/STAT3/VEGF pathways.
Du G; Zhu H; Yu P; Wang H; He J; Ye L; Fu F; Zhang J; Tian J
Eur J Pharmacol; 2013 Jan; 700(1-3):173-80. PubMed ID: 23276662
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Src/STAT3 signaling-mediated angiogenesis is involved in the anti-melanoma effects of dioscin.
Liu YX; Xu BW; Niu XD; Chen YJ; Fu XQ; Wang XQ; Yin CL; Chou JY; Li JK; Wu JY; Bai JX; Wu Y; Li SM; Yu ZL
Pharmacol Res; 2022 Jan; 175():105983. PubMed ID: 34822972
[TBL] [Abstract][Full Text] [Related]
11. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
[TBL] [Abstract][Full Text] [Related]
12. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway.
Wang SJ; Sun B; Cheng ZX; Zhou HX; Gao Y; Kong R; Chen H; Jiang HC; Pan SH; Xue DB; Bai XW
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1421-30. PubMed ID: 21479633
[TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner.
Yu R; Jin L; Li F; Fujimoto M; Wei Q; Lin Z; Ren X; Jin Q; Li H; Meng F; Jin G
J Dermatol Sci; 2020 Sep; 99(3):193-202. PubMed ID: 32859456
[TBL] [Abstract][Full Text] [Related]
15. ZYZ-803, a novel hydrogen sulfide-nitric oxide conjugated donor, promotes angiogenesis via cross-talk between STAT3 and CaMKII.
Xiong Y; Chang LL; Tran B; Dai T; Zhong R; Mao YC; Zhu YZ
Acta Pharmacol Sin; 2020 Feb; 41(2):218-228. PubMed ID: 31316179
[TBL] [Abstract][Full Text] [Related]
16. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells.
Lin R; Zhang Z; Chen L; Zhou Y; Zou P; Feng C; Wang L; Liang G
Cancer Lett; 2016 Oct; 381(1):165-75. PubMed ID: 27477901
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.
Bid HK; Oswald D; Li C; London CA; Lin J; Houghton PJ
PLoS One; 2012; 7(4):e35513. PubMed ID: 22530037
[TBL] [Abstract][Full Text] [Related]
18. The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs.
Chuang IC; Yang CM; Song TY; Yang NC; Hu ML
Life Sci; 2015 Oct; 139():52-61. PubMed ID: 26285173
[TBL] [Abstract][Full Text] [Related]
19. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
Shen M; Zhou XZ; Ye L; Yuan Q; Shi C; Zhu PW; Jiang N; Ma MY; Yang QC; Shao Y
Int J Mol Med; 2018 Aug; 42(2):769-778. PubMed ID: 29717775
[TBL] [Abstract][Full Text] [Related]
20. Farrerol inhibited angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway.
Dai F; Gao L; Zhao Y; Wang C; Xie S
Phytomedicine; 2016 Jun; 23(7):686-93. PubMed ID: 27235707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
